8.10
+0.2(+2.53%)
Currency In USD
| Previous Close | 7.9 |
| Open | 7.73 |
| Day High | 8.13 |
| Day Low | 7.67 |
| 52-Week High | 12.34 |
| 52-Week Low | 2.24 |
| Volume | 609,473 |
| Average Volume | 980,687 |
| Market Cap | 378.29M |
| PE | -2.16 |
| EPS | -3.75 |
| Moving Average 50 Days | 10.6 |
| Moving Average 200 Days | 6.34 |
| Change | 0.2 |
If you invested $1000 in 4D Molecular Therapeutics, Inc. (FDMT) since IPO date, it would be worth $200 as of December 25, 2025 at a share price of $8.1. Whereas If you bought $1000 worth of 4D Molecular Therapeutics, Inc. (FDMT) shares 3 years ago, it would be worth $399.61 as of December 25, 2025 at a share price of $8.1.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease
GlobeNewswire Inc.
Dec 17, 2025 12:00 PM GMT
Clinically meaningful lung function activity, measured by ppFEV1 and LCI2.5, with follow-up through 1 year at dose selected for Phase 2 Durable CFTR transgene expression within target therapeutic range with follow-up through at least 1 year Data supp
4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference
GlobeNewswire Inc.
Dec 08, 2025 1:00 PM GMT
EMERYVILLE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatmen
4DMT to Participate in 8th Annual Evercore Healthcare Conference
GlobeNewswire Inc.
Nov 20, 2025 1:00 PM GMT
EMERYVILLE, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatmen